Free Trial

Voloridge Investment Management LLC Has $14.25 Million Position in InMode Ltd. (NASDAQ:INMD)

InMode logo with Medical background

Voloridge Investment Management LLC lessened its position in InMode Ltd. (NASDAQ:INMD - Free Report) by 19.2% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 853,541 shares of the healthcare company's stock after selling 203,193 shares during the quarter. Voloridge Investment Management LLC owned approximately 1.23% of InMode worth $14,254,000 as of its most recent filing with the SEC.

Other large investors have also recently bought and sold shares of the company. Raymond James Financial Inc. bought a new stake in shares of InMode in the 4th quarter valued at about $1,332,000. Barclays PLC grew its stake in InMode by 113.5% in the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock valued at $2,876,000 after buying an additional 90,173 shares during the last quarter. Atlas Legacy Advisors LLC acquired a new position in shares of InMode during the 4th quarter worth approximately $848,000. Townsquare Capital LLC grew its position in shares of InMode by 43.2% during the 4th quarter. Townsquare Capital LLC now owns 17,029 shares of the healthcare company's stock worth $284,000 after purchasing an additional 5,137 shares in the last quarter. Finally, PNC Financial Services Group Inc. grew its position in shares of InMode by 17.7% during the 4th quarter. PNC Financial Services Group Inc. now owns 21,208 shares of the healthcare company's stock worth $354,000 after purchasing an additional 3,193 shares in the last quarter. Institutional investors and hedge funds own 68.04% of the company's stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on INMD. Barclays cut their price target on shares of InMode from $29.00 to $24.00 and set an "overweight" rating for the company in a report on Wednesday, April 30th. Robert W. Baird downgraded shares of InMode from an "outperform" rating to a "neutral" rating and cut their price target for the stock from $22.00 to $16.00 in a report on Monday, April 28th. Canaccord Genuity Group cut their price target on shares of InMode from $17.00 to $15.00 and set a "hold" rating for the company in a report on Tuesday, April 29th. UBS Group cut their price target on shares of InMode from $19.00 to $16.25 and set a "neutral" rating for the company in a report on Tuesday, April 29th. Finally, Jefferies Financial Group cut their price target on shares of InMode from $16.00 to $15.00 and set a "hold" rating for the company in a report on Monday, April 14th. Seven analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. According to MarketBeat.com, InMode currently has a consensus rating of "Hold" and a consensus price target of $18.54.

Check Out Our Latest Analysis on INMD

InMode Stock Up 2.2%

Shares of INMD stock traded up $0.31 during trading hours on Tuesday, hitting $14.54. 1,301,710 shares of the company's stock traded hands, compared to its average volume of 1,188,611. The stock has a market cap of $919.06 million, a PE ratio of 6.19 and a beta of 2.02. InMode Ltd. has a 12 month low of $13.68 and a 12 month high of $19.85. The stock's 50 day simple moving average is $15.52 and its 200 day simple moving average is $17.17.

InMode (NASDAQ:INMD - Get Free Report) last issued its quarterly earnings data on Monday, April 28th. The healthcare company reported $0.31 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $0.45 by ($0.14). The company had revenue of $77.87 million for the quarter, compared to the consensus estimate of $82.21 million. InMode had a return on equity of 18.25% and a net margin of 45.91%. InMode's revenue was down 3.0% compared to the same quarter last year. During the same quarter last year, the business earned $0.32 earnings per share. As a group, equities research analysts expect that InMode Ltd. will post 1.75 EPS for the current fiscal year.

About InMode

(Free Report)

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.

Featured Stories

Institutional Ownership by Quarter for InMode (NASDAQ:INMD)

Should You Invest $1,000 in InMode Right Now?

Before you consider InMode, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and InMode wasn't on the list.

While InMode currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

Beginner's Guide To Retirement Stocks Cover

Enter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

NVIDIA Earnings Preview: HUGE Stock Move Ahead
These 5 Small Stocks Could Deliver Huge Returns
ACT FAST! Congress Is POURING Into This Stock

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines